The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease

(Cell Metabolism 33, 1–17.e1–e8, October 5, 2021) In the originally published article, there were some textual errors in Figure 3. In Figure 3A, “Bilateral I/R 30mins” should above “d0.” In Figure 3F, the abscissa of the statistical chart should be “after I/R d28,” not “after I/R d5.” In addition, in the main text the supplement of L. casei Zhang should be 4 × 109 CFU per day, instead of the original 1 × 109 CFU per day. These errors have now been corrected online. The errors do not affect the presented data, analysis, or conclusions reported in the paper. The authors apologize for any confusion that these errors may have caused.Figure 3. L. casei Zhang provides renoprotection not entirely dependent on the original intestinal microflora (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) The probiotic L. casei Zhang slows the progression of acute and chronic kidney diseaseZhu et al.Cell MetabolismJuly 15, 2021In BriefZhu et al. demonstrate that the probiotic L. casei Zhang slows kidney disease progression in mouse models and individuals with chronic kidney disease (CKD) through increasing the levels of short-chain fatty acids and via nicotinamide metabolism, which together modulate the inflammatory response of local macrophages and tubular epithelia cells. These findings suggest a potential therapeutic approach for acute kidney injury and CKD. Full-Text PDF